- Patient Education
Clinical Trials At The IMSMP
Clinical trials help doctors and scientists test the safety and effectiveness of new or investigational medications and treatments. Many of the medications used at the IMSMP were tested in clinical trials to demonstrate their effectiveness in treating MS. Clinical trials have both potential risks and benefits for people who participate in them. Ineffective medication and possible side effects are potential risks while receiving treatment otherwise unavailable and helping others with MS by contributing to medical research are among the potential benefits. The IMSMP also participates in a number of research projects in collaboration with the Tisch MS Research Center of New York. For more information, please visit: www.tischms.org
Below are some of the current clinical trials being conducted at the IMSMP.
FDA-Approved Phase II Stem Cell Clinical Trial for MS
In conjunction with the Tisch MS Research Center, we have an FDA-approved clinical trial that uses intrathecal autologous mesenchymal stem cells with the goal of repairing the damage done in MS. For more information on this groundbreaking research, please visit: www.tischms.org/phase2
This study evaluates the features of patients with a benign MS disease course in an effort to better understand and define this clinical entity.
The IMSMP is a participating site in a multi-center study that investigates the effectiveness of disease-modifying therapies (DMTs) on relapse-remitting MS (RRMS) patients. The study will follow RRMS patients treated with Tecfidera, Copaxone, Aubagio, or Gilenya to evaluate the relative effectiveness of these disease-modifying therapies.
iConquerMS™ OPT-UP Study
The IMSMP/Tisch MS Research is also involved in iConquerMS™, a project associated with the Accelerated Cure Project. iConquerMS™ empowers patients living with MS to independently enter their health data into a secure online database. This data will be analyzed in conjunction with that of thousands of other MS patients, allowing these individuals to contribute their data and ideas to the advancement of research. Visit http://iConquerMS.org.
We continue to further investigate the novel administration of this medication for MS, the protocol of which was created by Dr. Sadiq many years ago. Currently, we are systematically following patients to evaluate efficacy and safety, evaluating CSF biomarkers of treated patients, and reporting on the long-term safety of our patients who have continued on this treatment for over 3 years.
JC Virus Antibody Titers
We are compiling data on the long-term stability of JC virus antibody titers in patients on Tysabri. The aim of this study is to examine whether antibody titers are predictive of future risk of an infection called progressive multifocal leukoencephalopathy (PML). PML is a serious, but rare, brain infection that has been seen in several of our immune-modifying treatments.
Lymphocyte Subsets Analysis
We are also investigating how various MS treatments, such as Tecfidera and Gilenya, affect sub-populations of certain immune cells and how that may impact patients clinically.
Memory and Multiple Sclerosis
The IMSMP is a participating site in a Kessler Foundation project that examines the effect of a memory retraining technique in patients with MS.
We are continuing to investigate the use of Rituximab in MS in various projects. One such project is following patients who transition from Tysabri to Rituximab to further evaluate this medication’s safety and efficacy.
The IMSMP is investigating the role of weekly plasmapheresis in patients with progressive forms of MS. Plasmapheresis filters the blood of immunoglobulins, which may be causing damage to the central nervous system.
For more information on any new clinical research please call (212) 265-8070